United Therapeutics Corporation Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- United Therapeutics Corporation payments for repurchase of common stock for the quarter ending 2026-06-30 was $0.00.
- United Therapeutics Corporation payments for repurchase of common stock for the quarter ending 2026-03-31 was $1.50B.
- United Therapeutics Corporation payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- United Therapeutics Corporation payments for repurchase of common stock for the quarter ending 2025-09-30 was $1.00B.
- United Therapeutics Corporation payments for repurchase of common stock for fiscal 2025 was $1.00B, a 0.00% change from fiscal 2024.
- United Therapeutics Corporation payments for repurchase of common stock for fiscal 2024 was $1.00B.
- United Therapeutics Corporation payments for repurchase of common stock for fiscal 2023 was $0.00.
- United Therapeutics Corporation payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.50B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.50B 10-Q · filed 2026-05-06 | $2.50B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.00B 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.00B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.00B 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.00B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $1.00B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.00B 10-Q · filed 2025-04-30 | $1.00B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $250.00M 10-K · filed 2020-02-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | |
| 2016-12-31 | $104.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $500.00M 10-K · filed 2019-02-27 |
| 2016-09-30 | $135.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $395.50M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-06-30 | $136.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $317.40M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-03-31 | $123.20M 10-Q · filed 2017-04-26 | $365.40M derived: sum of 4 quarters · filed 2018-02-21 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $394.50M 10-K · filed 2018-02-21 |
| 2015-09-30 | $57.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $474.44M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-06-30 | $184.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $442.34M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-03-31 | $152.30M 10-Q · filed 2016-04-28 | $537.77M derived: sum of 4 quarters · filed 2017-02-22 |
| 2014-12-31 | $79.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $483.10M 10-K · filed 2017-02-22 |
| 2014-09-30 | $25.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $403.16M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $279.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $377.56M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $97.63M 10-Q · filed 2015-04-28 | $134.17M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $42.44M 10-K · filed 2016-02-25 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $99.51M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $36.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $142.44M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $5.90M 10-Q · filed 2014-04-29 | |
| 2012-12-31 | $57.08M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $188.00M 10-K · filed 2015-02-24 |
| 2012-09-30 | $42.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | |
| 2011-12-31 | $212.00M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |